These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 9222272)

  • 61. Parkinson's disease therapy: treatment of early and late disease.
    Jankovic J
    Chin Med J (Engl); 2001 Mar; 114(3):227-34. PubMed ID: 11780303
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Parkinson's disease: managing symptoms and preserving function.
    Sweeney PJ
    Geriatrics; 1995 Sep; 50(9):24-31. PubMed ID: 7672615
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [TBL] [Abstract][Full Text] [Related]  

  • 65. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Zonisamide has beneficial effects on Parkinson's disease patients.
    Murata M; Horiuchi E; Kanazawa I
    Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dopamine agonists and neuroprotection in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2002 Nov; 9 Suppl 3():7-14. PubMed ID: 12464116
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rationale for dopamine agonist use as monotherapy in Parkinson's disease.
    Schwarz J
    Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S27-33. PubMed ID: 15180135
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Treatment of early Parkinson's disease].
    Delvaux V; Moonen G; Garraux G
    Rev Med Liege; 2009 Apr; 64(4):228-32. PubMed ID: 19514544
    [TBL] [Abstract][Full Text] [Related]  

  • 71. 'Bad guys' among the antiparkinsonian drugs.
    Pirtosek Z
    Psychiatr Danub; 2009 Mar; 21(1):114-8. PubMed ID: 19270634
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The relevance of preclinical studies for the treatment of Parkinson's disease.
    Gerlach M; Foley P; Riederer P
    J Neurol; 2003 Feb; 250 Suppl 1():I31-4. PubMed ID: 12761633
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dopamine agonists in Parkinson's disease.
    Yamamoto M; Schapira AH
    Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.
    Gerlach M; Double K; Reichmann H; Riederer P
    J Neural Transm Suppl; 2003; (65):167-83. PubMed ID: 12946055
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Parkinson's disease: diagnosis, pathology, and treatment.
    Sethi KD
    J Med Assoc Ga; 1997 Apr; 86(2):89-96. PubMed ID: 9114653
    [No Abstract]   [Full Text] [Related]  

  • 78. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
    Olanow CW
    Mov Disord; 1993; 8 Suppl 1():S1-7. PubMed ID: 8302302
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Ahlskog JE
    Neurology; 2003 Feb; 60(3):381-9. PubMed ID: 12580184
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of early Parkinson's disease. Part 2.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):206-15. PubMed ID: 19176961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.